Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) CEO David M. Stack sold 58,885 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $38.34, for a total value of $2,257,650.90. Following the sale, the chief executive officer now owns 159,164 shares of the company’s stock, valued at $6,102,347.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) traded up $0.75 during trading on Friday, hitting $40.25. The stock had a trading volume of 710,957 shares, compared to its average volume of 843,788. Pacira Pharmaceuticals, Inc. has a twelve month low of $29.81 and a twelve month high of $58.95. The company has a current ratio of 6.99, a quick ratio of 6.24 and a debt-to-equity ratio of 1.03.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings results on Wednesday, November 8th. The company reported $0.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The business had revenue of $67.30 million for the quarter, compared to analyst estimates of $68.99 million. During the same quarter in the prior year, the company posted $0.20 EPS. The company’s quarterly revenue was down 1.6% on a year-over-year basis. equities analysts forecast that Pacira Pharmaceuticals, Inc. will post -0.87 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Pacira Pharmaceuticals, Inc. (PCRX) CEO David M. Stack Sells 58,885 Shares” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.dailypolitical.com/2017/11/18/pacira-pharmaceuticals-inc-pcrx-ceo-david-m-stack-sells-58885-shares.html.

Several analysts recently commented on PCRX shares. Canaccord Genuity set a $56.00 price target on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, July 25th. Mizuho reiterated a “buy” rating and set a $54.00 price target on shares of Pacira Pharmaceuticals in a research report on Wednesday, July 26th. Royal Bank Of Canada set a $58.00 price target on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, July 30th. HC Wainwright set a $59.00 price target on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Finally, Needham & Company LLC started coverage on Pacira Pharmaceuticals in a research report on Tuesday, August 22nd. They set a “buy” rating and a $55.00 price target for the company. Three analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $49.71.

Several institutional investors have recently made changes to their positions in PCRX. BlackRock Inc. lifted its stake in shares of Pacira Pharmaceuticals by 28,922.7% in the 1st quarter. BlackRock Inc. now owns 3,183,787 shares of the company’s stock valued at $145,180,000 after purchasing an additional 3,172,817 shares during the last quarter. HealthCor Management L.P. lifted its stake in shares of Pacira Pharmaceuticals by 63.1% in the 2nd quarter. HealthCor Management L.P. now owns 1,793,799 shares of the company’s stock valued at $85,564,000 after purchasing an additional 693,799 shares during the last quarter. Eaton Vance Management purchased a new stake in shares of Pacira Pharmaceuticals in the 2nd quarter valued at $19,519,000. Mesirow Financial Investment Management Equity Management purchased a new stake in shares of Pacira Pharmaceuticals in the 3rd quarter valued at $14,671,000. Finally, Stonepine Capital Management LLC purchased a new stake in shares of Pacira Pharmaceuticals in the 3rd quarter valued at $14,089,000. 99.64% of the stock is currently owned by institutional investors and hedge funds.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Insider Buying and Selling by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.